Your browser doesn't support javascript.
loading
Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes.
Usatin, Danielle; Yen, Elizabeth H; McDonald, Catherine; Asfour, Fadi; Pohl, John; Robson, Jacob.
Affiliation
  • Usatin D; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, CA, United States.
  • Yen EH; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, CA, United States.
  • McDonald C; Primary Children's Hospital, Salt Lake City, UT, United States.
  • Asfour F; Division of Pediatric Pulmonology, Department of Pediatrics, Primary Children's Hospital, University of Utah School of Medicine, Salt Lake City, UT, United States.
  • Pohl J; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Primary Children's Hospital, University of Utah School of Medicine, Salt Lake City, UT, United States.
  • Robson J; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Primary Children's Hospital, University of Utah School of Medicine, Salt Lake City, UT, United States. Electronic address: Jacob.robson@hsc.utah.edu.
J Cyst Fibros ; 16(4): 503-509, 2017 Jul.
Article in En | MEDLINE | ID: mdl-27989470
ABSTRACT

BACKGROUND:

Early childhood growth status has been used to predict long-term clinical outcomes in Cystic Fibrosis (CF) patients. Adulthood CF outcomes based on early weight-for-length (WFL) measurements, using either World Health Organization (WHO) or Centers for Disease Control (CDC) scales, have not been compared.

METHODS:

Cystic Fibrosis Foundation registry patients were studied (n=3014). Participants were categorized at age two years as WFL <50th percentile on both WHO and CDC scales, ≥50th percentile on WHO but not CDC, or ≥50th percentile on both. Pulmonary function and overall survival were assessed at age 18years.

RESULTS:

Stepwise gains in pulmonary function and lung transplant-free survival were noted across the three increasing WFL categories.

CONCLUSIONS:

Children with CF who achieve higher WFL at age two years have improved pulmonary and survival outcomes into adulthood. CF providers should continue to utilize current early growth recommendations, with goal WFL ≥50th percentile on CDC growth charts before age two.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Height / Anthropometry / Cystic Fibrosis / Growth Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Adolescent / Child, preschool / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: J Cyst Fibros Year: 2017 Document type: Article Affiliation country: United States Publication country: HOLANDA / HOLLAND / NETHERLANDS / NL / PAISES BAJOS / THE NETHERLANDS

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Height / Anthropometry / Cystic Fibrosis / Growth Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Adolescent / Child, preschool / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: J Cyst Fibros Year: 2017 Document type: Article Affiliation country: United States Publication country: HOLANDA / HOLLAND / NETHERLANDS / NL / PAISES BAJOS / THE NETHERLANDS